Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 5 of 5 for “"somatostatin receptor-2"”.
-
Atherosclerotic inflammation imaging using somatostatin receptor-2 positron emission tomography
… Up-regulation of the G-protein coupled receptor somatostatin receptor subtype-2 (SST2) occurs on the cell surface of activated macrophages. The central hypothesis tested in this thesis is that vascular SST2 PET imaging using 68Ga-DOTATATE might offer a more accurate marker of macrophage …
-
Somatostatin Receptor 2 Regulation By C-Terminal Motifs and Pdz Domain Proteins
<p>Somatostatin receptor 2 (sst2) is a Gi-coupled G-protein coupled receptor that mediates many of somatostatin’s neuroendocrine actions. Sst2 is a clinically important GPCR as it is the drug target of somatostatin analogs such as octreotide, lanreotide, and pasireotide. Treatment with these …
-
Effects Of Sustained Release Somatostatin Type 2 Antagonism On Glucagon Counterregulation And Glycemia In Type 2 Diabetic Rate Model
This thesis examined whether a novel somatostatin receptor 2 antagonist (SSTR2a), ZT-01, could enhance endogenous glucagon secretion and protect against hypoglycemia in a rat model of type 2 diabetes (T2D). Male Sprague Dawley rats were placed on a high-fat diet and injected with streptozotocin to …
-
A BIOMARKER ENRICHMENT PHASE II TRIAL OF 177LU-DOTATATE IN METASTATIC NASOPHARYNGEAL CANCER WITH A SAFETY RUN-IN
… the prevalence and prognostic significance of somatostatin receptor 2 (SSTR2) expression in an international study comprising multiple clinical cohorts of 402 primary, locally recurrent and metastatic NPCs. We found significant correlation of SSTR expression with increased rates of survival and …
-
Targeted radiotherapy in metastatic neuroendocrine tumours: clinical and experimental studies
… the possibility for curative surgery. Peptide receptor radiotherapy (PRRT) with 177Lu-DOTATATE targets somatostatin receptors, which are overexpressed on NET cells. PRRT results in symptom relief and often tumour control of NETs, but rarely cure. Tumour response is variable and renal and …